Keeping you up to date on recent developments in orthopedics, including: New opportunities for detecting osteoporosis; Brazilian researchers discover how muscle regenerates after exercise; Different outcomes by race/ethnicity among patients with COVID-19 and rheumatic disease.
HONG KONG – Humanigen Inc. has executed its first licensing agreement in the Asia-Pacific region, in a deal worth up to $20 million that gives Telcon RF Pharmaceutical Inc. and KPM Tech Co. Ltd. the development and commercialization rights to lenzilumab for COVID-19 in South Korea and the Philippines.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Axsome, Bristol, Equillium, Generex, Ionis, Jubilant, Myokardia, Novan, Novavax, Ocular, Pfizer, Prothena, Salliant, Sofie.
The latest global regulatory news, changes and updates affecting medical devices and technologies, including: FDA announces recall of discontinued Medtronic catheter.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Biolytical Laboratories, DNA Genotek, Pari Pharma, Salvia Bioelectronics.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alveo Technologies, Biocartis Group, Coloplast, Decision Diagnostics, DJO Global, Endpoint Health, Geneprodx, Hutchinson Technology, Joline, Mir Scientific, Morton Comprehensive Health Services, Motus GI, Nine Continents Medical, Novarad, Ossdsign, Oxford Gene Technology, Remark Holdings, Resonetics, Sirakoss, Stryker, Wright Medical Group.
A multimillion dollar windfall for Icosavax Inc. will help allow the company to launch a COVID-19 vaccination program using its virus-like particle candidate (VLP), IVX-411, that displays the SAR-CoV-2 receptor-binding domain.
The dramatic increase in COVID-19 infections in Europe and the U.S., combined with information overload surrounding the lead up to the Nov. 3 contentious U.S. presidential election, was more than enough to send investors to the sidelines in October.
RSS
